Eledon Pharmaceuticals Expects To Present 24-Month Data From 8 Participants In Phase 1 Extension Study Evaluating Tegoprubart In Kidney Transplantation In 2026; Report Other Data From Phase 1, 2 BESTOW Trials
Benzinga Newsdesk 10 months ago
News
Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.
Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.